Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa study of intratumoral CNSI-Fe in advanced solid tumors
CTR20243192Phase 2Active
- Sponsor
- Sichuan Yingrui Pharmaceutical Technology
- Start
- Nov 2024
- Modality
- Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of CNSI-Fe in Nonhematologic neoplasms, Bone and soft tissue sarcoma, head and neck cancer (HNC), thyroid cancer, breast cancer, sponsored by Sichuan Yingrui Pharmaceutical Technology. Started Nov 2024; status: active.
02
Drugs
CNSI-Fe
03
Conditions
Nonhematologic neoplasmsBone and soft tissue sarcomahead and neck cancer (HNC)thyroid cancerbreast cancer
Beyond the preview
Go deeper on CTR20243192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243192.